News
Filter by year:
-
STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Phase 2 Sarcoma Trial of STC‑15
-
Lightcast Raises $27 Million and Adds Industry Veteran to Accelerate Commercialization of Envisia™ Platform
-
Repronovo Appoints Mark Altmeyer as Chairman of the Board
-
Enara Bio to Unveil First‑in‑Class DARKFOX‑Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential for Solid Tumor Immunotherapy
-
Outrun Therapeutics unveils lead programme targeting HPV positive head and neck cancer and appoints renowned E3 ligase experts to Scientific Advisory Board (SAB)
-
Artios Reports Randomized Phase 2a Study of Low Dose Alnodesertib Plus Gemcitabine Achieves Primary Endpoint in Platinum-Resistant Ovarian Cancer
-
Celebrate women in science with Optimum
-
Artios Receives U.S. FDA Fast Track Designation for DNA Polymerase Theta (Polθ) Inhibitor ART6043 for Treatment of gBRCA-mutated HER2-Negative Breast Cancer
-
Concerto Biosciences Signs Development and Commercialization Agreement with Sacco System to Advance Next-Generation Microbial Ingredient Discovery
-
UNISERS Ships First Fully-Automated Fab Tool and Strengthens Leadership to Scale In-Fab Deployment
-
SEEQC and Allegro Merger Corp. Enter Into Merger Agreement
-
Nouscom Highlights Potential of NOUS-209 to Intercept Cancer in Lynch Syndrome Carriers in Seminal Nature Medicine Publication
-
Altoida and Mindspan Announce Research Collaboration to Use AI/AR-Powered Digital Cognitive Assessment to Personalize Cognitive Care
-
Iktos named Top BioTech and Life Sciences Companies of 2025
-
Iktos Enters Strategic €1B+ Multi-Target AI Partnership with Servier to Advance Drug Discovery in Oncology and Neurology
-
Pierre Fabre Laboratories and Iktos announce Integrated Drug Discovery Collaboration
-
DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies
-
M Ventures: Pharma CVC and biotech innovation in 2026
-
NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS/MND and Parkinson’s
-
Mosa Meat Secures Additional €15M in Funding and Reaches Cost Parity Milestone, Preparing for Commercial Launch
-
Lucidean Raises Series Seed Funding to Accelerate Next-Gen Coherent Optical Links for Data Centers
-
Actithera appoints radiopharmaceutical pioneer Dr. Darshan Dalal as Chief Medical Officer
-
Theolytics to Present Ongoing Phase I/IIa OCTOPOD-IV Trial of THEO-260 in Ovarian Cancer at ESMO 2025
-
REPRONOVO ANNOUNCES CLINICAL TRIAL APPROVAL NOTICE FOR RPN-001 IN CHINA
-
Artios Receives U.S. FDA Fast Track Designation for alnodesertib in ATM-negative Metastatic Colorectal Cancer (mCRC)
-
TRIMTECH Therapeutics named as one of Fierce Biotech’s ‘Fierce 15’ for 2025
-
NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND
-
Polaris Announces Series A Funding Led by Koch Disruptive Technologies and Appoints Industry Veteran Morten Nissov as CEO to Accelerate Growth
-
Actithera Raises $75.5M in Oversubscribed Series A Financing to Redefine Precision Radioligand Therapy
-
ReproNovo Announces First Participant Included in U.S. Phase 2 Trial of RPN-001 for Male Infertility
-
NTT DATA and Corvic AI Partner on GenAI Value Drivers
-
M Ventures Announces Key Leadership Changes in Technology Investment Team
-
ReproNovo raises $65 Million Series A Financing to advance phase 2 clinical trials of novel therapies in reproductive medicine and Womens's Health
-
Enara Bio Strengthens Senior Leadership with Key Executive and Board Appointments Alongside Acceleration of Multiple T-Cell Engager Programs
-
M Ventures co-leads $18.7M Series A investment in ChEmpower
-
Corvic AI Raises $12M in Seed Funding to Pioneer AI Cognitive Infrastructure for Enterprise Intelligence
-
Vizgen Announces New Appointments to Board of Directors and Executive Leadership Team
-
Celestial AI Secures $250 Million Funding to Revolutionize AI Infrastructure with Its Photonic Fabric
-
TRIMTECH Therapeutics raises $31M to advance targeted protein degradation for treatment of neurodegenerative diseases
-
Concerto Biosciences Announces Appointment of Dr. Stewart Campbell to Board of Directors
-
NovoLINC Secures Investments to Assist AI Computing with Groundbreaking Thermal Interface Technology
-
Outrun Therapeutics expands leadership team with appointment of Matthew Fyfe as Chief Scientific Officer
-
Tignis has been acquired by Cohu to Enhance Data Analytics and AI/ML Platform
-
Ribometrix Strengthens Leadership by appointing William S. Marshall as CEO and Katie Warner as CSO
-
Abselion raises £6.6 million led by M Ventures to bring disruptive at-line protein analyser, Amperia, to market
-
Concerto Biosciences Announces First Participant Dosed with Live Biotherapeutic ENS-002 in Phase 1 Trial for Atopic Dermatitis
-
Nouscom Completes Patient Enrollment of Randomized Phase 2 Study Evaluating NOUS-209, an Off-the-Shelf Neoantigen Immunotherapy, in dMMR/MSI Metastatic Colorectal Cancer
-
IonKraft secures € 3.5 M equity funding to fuel circular economy in packaging
-
Kivu Bioscience Raises $92 Million Series A Led by Novo Holdings to Advance Next-Generation Antibody-Drug Conjugates
-
Enara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens
-
PictorLabs Raises $30 Million in Series B Funding to Accelerate AI-Powered Virtual Staining Technology
-
NanoSyrinx closes c. £10 million GBP financing and appoints Dr. Edwin Moses as Chairman
-
Formo bags $61 million in Series B funding - launches the world’s first animal-free cheese made with Koji Protein
-
Scrona AG and Electroninks Announce Collaboration in Materials and Process Development for Advanced Semiconductor Packaging
-
Electroninks Launches World-First Copper MOD Ink to Revolutionize Advanced Semiconductor Packaging
-
Thintronics Inc. Closes Its Series A Extension
-
Hakan Goker Managing Director of M Ventures in Nature Biotech
-
Confidential Computing is Key for AI-driven Collaboration
-
Anjuna Raises $25M Funding to Fuel Momentum and Expand Confidential Computing Offerings for AI
-
M Ventures Participates in Asceneuron's $ 100M Series C Financing to Advance Groundbreaking Therapeutics in Neurodegenerative Diseases
-
Metalenz wins AI Breakthrough Award for Best Overall Biometrics Solution
-
Celestial AI's $175M Series C Highlighted in Crunchbase News
-
iOnctura announces EUR80 million Series B financing to progress pipeline through Phase II trials
-
Quintessent CEO Alan Liu on Photonic Chip Technology
-
Celestial AI: One Of The 10 Hottest Semiconductor Startups Of 2024
-
LabGenius raises £35 million led by M Ventures to further develop its ML-driven antibody discovery platform and progress a pipeline of assets towards the clinic
-
Electroninks Opens New APAC Facility
-
Tignis' David Park discusses Predicting And Preventing Process Drift
-
Outrun launches with a $10m seed financing from M Ventures and MP Healthcare Venture
-
Mosa Meat Raises €40M in New Financing
-
Merck KGaA, Darmstadt, Germany’s Corporate Venture M Ventures Arm Backs Nucleai to Advance Its First-in-class Spatial AI Biomarker in Active Clinical Enrollment
-
Biolinq Raises $58 Million to Advance Wearable Biosensors Through Pivotal Trial for Metabolic Health Using Precision Microsensor Technology
-
Asceneuron Joins Critical Path for Alzheimer’s Disease Consortium
-
Mike Grey appointed Executive Chair of Theolytics’ Board of Directors
-
Sonde Health's new app can help with your mental health simply by hearing your voice
-
Chip Startup Celestial AI Lands Massive $175M Series C
-
Quintessent Raises $11.5M In Seed Funding To Future-Proof Optical Connectivity
-
beeOLED welcomes New Advisory Board Member and Chairman Gerd Günther
-
Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases
-
Metalenz joins forces with Samsung to scale polarization ID sensor
-
Plexium Announces Appointment of Michael Martin, Ph.D. as President and CEO
-
DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing
-
M Ventures portfolio company Calypso, a Merck KGaA, Darmstadt, Germany spin-out, enters into agreement to be acquired by Novartis
-
Polaris Electro-Optics, Inc. Raises Seed Round to Revolutionize Optical Interconnects
-
M Ventures co-leads a €67.5 million oversubscribed Series C round for cancer immunotherapy company Nouscom
-
STORM Therapeutics Appoints Marguerite Hutchinson, J.D., as Chief Business Officer
-
CEGYR leads as first fertility clinic globally to use Future Fertility’s AI-powered egg assessment on all cycles
-
CellFE secures $22 million in Series A financing
-
Anavo Therapeutics Strengthens Management Team
-
Astraveus raises €16.5 Million Series Seed round
-
Metalenz Launches its Metasurface Optics on the Open Market in Partnership with UMC
-
DNA Script Raises $38.5 Million in Series B Financing
-
Altoida Appoints Marc Jones as Chief Executive Officer
-
Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
-
Anavo Therapeutics extends Seed Round to € 28m
-
ImmuneBridge Raises $12M from M Ventures and Insight Partners
-
OBE022 Exerts a Synergistic Effect in Combination with Standard of Care
-
SEEQC Unveils First Fully Digital Chips for Full-Stack Quantum Computers
-
Synaffix Announces Expansion of ADC Collaboration with MacroGenics
-
Iktos raises € 15.5m Series A round
-
iOmx Therapeutics appoints Dr. Christine Rothe as new CDO
-
UNISERS Raises $14M Seed Round
-
Explore Applications of Quantum Computing in Chemical Reactions for Industrial Use
-
Effortlessly Develop and Deploy AI on MemryX Edge AI Processors
-
Chong Kun Dang Pharm Licenses Synaffix ADC Technology
-
Metalenz Wins 2023 Prism Award
-
Purple Biotech acquires Immunorizon and Its Portfolio of Tri-Specific Antibodies
-
Rewind Therapeutics Adds Sunstone Life Science Ventures A/S as New Investor
-
STORM Therapeutics Presents STC-15 Preclinical Data
-
STORM Therapeutics Expands R&D Leadership Team
-
iOnctura Provides Development Update on PI3Kδ Inhibitor
-
Synaffix Enters $2 Billion License Agreement with Amgen
-
First Patient Dosed in Phase 1/2a Study of IMT-009
-
Metalenz to Participate in EMD Electronics Tech Talks
-
Hummingbird Bioscience and Synaffix Enter $150m License Agreement
-
PictorLabs Launches with More Than $18.8 Million to Advance Transformative Virtual Staining
-
IOnctura Awarded EUR17.5 Million Funding From The EIC Accelerator For Clinical Development Of Novel Pancreatic Cancer Therapy
-
Calypso Biotech announces first patient with Eosinophilic Esophagitis dosed in antiInterleukin-15 (IL-15) monoclonal antibody CALY-002 Phase 1a/b Trial, and animal proof of concept data in Atopic Dermatitis
-
STORM Therapeutics announces closing of USD $30M Series B financing
-
Another Award for Synaffix: ‘Business Development Team of Year’ at the Scrip Awards
-
IOnctura Initiates Phase Ib Pancreatic Cancer Trial Of Next-Generation Autotaxin Inhibitor IOA-289
-
Electroninks Partners with Citrine Informatics to Develop Enhanced Silver Ink Using AI-Assisted R&D
-
Synaffix Named ‘Biotech Company of the Year’ at the LSX European Lifestars Awards
-
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results
-
Concerto Biosciences Raises $23 Million in Series A
-
M Ventures leads oversubscribed £37.5 million Series A financing of Nucleome Therapeutics
-
Synaffix Licenses CliCr® Chemistry from Cristal Therapeutics to Fortify Best-in-Class ADC Technology Offering
-
Theolytics presents CAF-targeting therapy for stromal rich tumours, and strengthens leadership team
-
Future Fertility's AI-powered oocyte-assessment tools receive CE Mark
-
Fierce Biotech names STORM Therapeutics as one of its “Fierce 15” Biotech Companies of 2022
-
STORM Therapeutics Appoints New CEO
-
Akili is now listed on Nasdaq
-
Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial Results
-
Plexium Appoints Brian Wong To Its Board of Directors
-
M Ventures Invests in TIGNIS for Sustainability in Semiconductor Mfg. in Series A
-
Metalenz and STMicroelectronics Deliver World’s First Optical Metasurface Technology for Consumer Electronics Devices
-
Scipio bioscience selected for €2.5M European Innovation Council grant
-
Altoida Appoints Neuroscience Pioneer Dr. Antontella Santuccione Chadha as Chief Medical Officer
-
Theolytics' £1M project with InnovateUK to develop a novel therapy for multiple myeloma patients
-
Asceneuron Awarded Second Grant from The Michael J. Fox Foundation
-
Plexium Appoints Stephen Mullennix as Chief Financial Officer
-
Future Fertility Announces New CEO
-
Abbvie and Plexium Enter into Multi-target Strategic Collaboration to Develop and Commercialize Targeted Protein Degradation Therapies for Neurological Conditions
-
Electroninks Announces Production-Scale Availability of Full Suite of Metal Complex Conductive Ink Solutions
-
SynSense steps into the field of smart cockpits by initiating a technological exploration with BMW
-
DNA Script Launches Early Access Program for Latest Advancements to the SYNTAX Platform and Enzymatic DNA Synthesis Technology
-
iOnctura data at AACR demonstrates unique mechanism of action for clinical stage autotaxin inhibitor IOA-289
-
DNA Script Partners with Asia-Pacific Distributors as Part of Global Expansion to Meet Demand for Same-day Enzymatic DNA Synthesis
-
Asceneuron Publishes Preclinical Efficacy Data on ASN90
-
Cybernews Interview with Metalenz Co-Founder and CEO Rob Devlin
-
Altoida upsizes its Series A Round to $20.3M to Advance Its First in Class AI-Powered Neurocognitive Assessment Platform
-
Dr Marie McAvoy joins NanoSyrinx as Chief Scientific Officer
-
iOnctura To Present Preclinical Data On Its Clinical Stage Autotaxin Inhibitor, IOA-289, At AACR
-
Akili Named to Fast Company’s Annual List of the World’s 50 Most Innovative Companies for 2022
-
NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets
-
DNA Script Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2022
-
Plexium Announces $102m Financing to Advance Pipeline of Targeted Protein Degradation Therapies and Technology Platform
-
DNA Script Joins Wellcome Leap R3 Program to Advance RNA Products and Therapies
-
Celestial AI Raises $56 Million Series A to Disrupt the Artificial Intelligence Chipset Industry with Novel Photonic-Electronic Technology Platform
-
Amgen and Plexium Announce Multi-year, Drug Discovery Collaboration to Identify Novel Targeted Protein Degradation Therapies
-
Akili to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I
-
Scipio bioscience launches commercialization in Europe of Asteria, its RNA sequencing kit
-
Metalenz Launches Gemini to Make 3D Sensing Easier with Selectable Illuminator Optics
-
Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors
-
Future Fertility Raises Series A to Progress First-In-Class AI-Enabled Fertility Solutions to Improve IVF Outcomes
-
Anavo Therapeutics Announces the Appointment of Charles McDermott as Chairman of the Board
-
AI Chip Innovator MemryX Hires Veteran Semiconductor Leader Keith Kressin as CEO
-
Merck KGaA, Darmstadt, Germany KGaA, Darmstadt, Germany, Expands Corporate Venture Fund M Ventures with a New Investment of € 600 Million
-
DNA Script Obtains CE Mark for SYNTAX DNA Printing Platform
-
Plexium Appoints Percival Barretto-Ko as President and Chief Executive Officer
-
DNA Script Raises $165M in Oversubscribed Series C Financing to Accelerate Commercialization of Enzymatic DNA Printing Platform
-
Xilio Therapeutics Announces Closing of Initial Public Offering
-
Xilio Therapeutics Announces FDA Clearance of Investigational New Drug Application for XTX202 for the Treatment of Solid Tumors
-
Altoida Launches 5-Year Multi-Center Alzheimer’s Study with Eisai and Ionian University
-
iOmx Therapeutics raises EUR 65 million in Series B round
-
Third ADC with Synaffix’s Technology Enters Clinical Development
-
Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX101 for the Treatment of Patients with Solid Tumors
-
Altoida Unveils New Brand Identity with Reimagined Logo and Website
-
Altoida Awarded FDA Breakthrough Designation for Development of World’s First Precision Neurology Device for Prediction of Alzheimer's Disease
-
NanoSyrinx announces oversubscribed £6.2M Seed+ funding round to develop its novel biologic delivery platform
-
Theolytics expands Series A financing and welcomes M Ventures as a new investor
-
Anavo Therapeutics Strengthens Scientific Advisory Board with Industry-Leading Drug Discovery Experts in Oncology
-
Xilio Therapeutics Announces Clinical Trial Collaboration With Merck KGaA, Darmstadt, Germany on Anti-CTLA-4 Monoclonal Antibody Program
-
Soteria Biotherapeutics Launches with $42 Million Series A Financing Led by Roche Venture Fund and 5AM Ventures
-
Anavo Therapeutics Launches with EUR 20 Million Seed Financing to Create Industry-Leading Pipeline of Allosteric Phosphatase Modulators
-
FoRx Therapeutics AG appoints Tarig Bashir as Chief Executive Officer
-
STORM Therapeutics Expands Scientific Advisory Board with the Appointment of Professor Tsutomu Suzuki
-
FORENDO PHARMA SUCCESSFULLY COMPLETES PHASE 1 STUDIES OF FOR-6219 IN ENDOMETRIOSIS, AIMING TO ADVANCE PROGRAM INTO PHASE 2 CLINICAL STUDIES
-
Xilio Therapeutics Raises $95 Million in Series C Financing to Advance Potent Tumor-Selective Immuno-Oncology Pipeline
-
Artios Pharma Announces the Start of First Clinical Study with the Dosing of its ATR Inhibitor, ART0380, to Patients
-
Plexium Announces $35m Financing to Advance Pipeline of Novel Protein Degraders
-
Merck KGaA, Darmstadt, Germany KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology
-
Ferroelectric Memory GmbH (FMC) Raises $20 Million to Accelerate Next-Generation Memory for AI, IoT, Edge Computing, and Data Center Applications
-
Calypso Biotech announces successful dosing of first Phase 1 cohort with anti-Interleukin-15 (IL-15) monoclonal antibody CALY-002 for the treatment of Autoimmune Diseases
-
Soteria Biotherapeutics Announces Scientific Advisory Board
-
Xilio Therapeutics Presents Promising Preclinical Tumor-Selective Efficacy and Safety Data for XTX201 (IL-2) and XTX101 (anti-CTLA-4) at SITC
-
Galecto Announces Pricing of Initial Public Offering
-
STORM Therapeutics selects first-in-class clinical candidate targeting METTL3
-
Synthetic Biology start up NanoSyrinx secures capital to develop its fully customisable platform for intra-cellular engineering
-
Galecto Raises $64 Million to Accelerate Development of Clinical Pipeline
-
Mosa Meat raises Series B funding to prepare for large-scale cultured meat production
-
Rapid prototyping and validation of SARS-CoV-2 clinical diagnostic workflows
-
Sonde Health purchases NeuroLex Labs’ voice platform and 500K biometric samples
-
DNA Script Expands Series B to $89M
-
Synaffix Announces Third Deal Expansion by ADC Therapeutics
-
Xilio Therapeutics Appoints Paul J. Clancy to its Board of Directors
-
Sonde Health Launches New Voice-Enabled Health Screening Tool to Help Employers Return to Work During the Global Pandemic
-
Micropsi Industries Secures Two New Specialized Investors
-
Akili Announces FDA Clearance of EndeavorRx™ for Children with ADHD, the First Prescription Treatment Delivered Through a Video Game
-
iOnctura Appoints Industry Veteran Dr. Joanna Horobin as Chair
-
Computers modelled on the human brain
-
Galecto Appoints New Chair and Strengthens Board of Directors
-
Xilio Therapeutics Appoints Martin H. Huber, M.D as Chief Medical Officer
-
Akili Announces ENDEAVORTM Digital Attention Treatment is Now Available for Children with Attention Deficit Hyperactivity Disorder (ADHD) under FDA’s COVID-19 Enforcement Discretion Guidance
-
FoRx Therapeutics AG Raises EUR 10 Million Seed Round
-
Seeqc Gains Over $11 Million in Funding to Introduce Fully Digital Quantum Computing
-
Scipio bioscience raises €6.0 M Series A financing
-
Artios Pharma Strengthens Clinical Development Team with Senior Appointments
-
iOnctura Expands its Clinical Advisory Board
-
Neurable raises $6 million to develop brain-sensing consumer devices, beginning with headphones
-
Berlin-based startup Legendairy Foods has raised €4M to develop cheese and other dairy products that have the same composition as milk but are not derived from animals
-
FORENDO PHARMA SIGNS IMPORTANT LICENSE AND COLLABORATION DEAL WITH LEADING PHARMA COMPANY
-
Immunitas Therapeutics Launches with $39 Million to Advance Lead Programs to Human Efficacy Studies Based on a Unique Immunology-Focused Drug Development Platform
-
NEC and VAXIMM Announce Collaboration to Advance Personalized Neoantigen Cancer Vaccines
-
Plexium Launches with $28 Million in Series A Financing
-
iOmx Therapeutics Announces Discovery of Novel, Druggable Immune-Checkpoint Targets
-
Artios Pharma appoints Tania Dimitrova as Chief Business Officer and expands presence in the United States
-
Riffyn Appoints Former Cisco and HP Executive Barbara Adey to Board of directors
-
Sunstone Life Science Ventures joins Forendo Pharma Investor Syndicate
-
First programmable memristor computer aims to bring AI processing down from the cloud
-
BASF is collaborating with Riffyn on white biotechnology R&D
-
John Conway, Former Head of Data Sciences and AI at AstraZeneca, Joins Riffyn as Chief Commercial Officer
-
Larry Peck, Former VP at Autodesk, Joins Riffyn as Vice President of Engineering
-
Riffyn Enters Multi-Year Contract with Novozymes for R&D Data Analytics
-
Altoida raises $6.3m Series A to Predict Alzheimer’s Disease Risk Using Artificial Intelligence, Machine Learning and Augmented Reality
-
Riffyn Raises a $15M Series B to Accelerate Its Growth in Life Sciences R&D
-
GE Healthcare and Indi Molecular to collaborate on diagnostic tool for clinical management of immunotherapy patients
-
Sonde Completes $16 Million Series A Financing Round to Advance Vocal Biomarker Technology
-
Artios Pharma Announces Appointment of Dr. Ian Smith as Chief Medical Officer
-
iOnctura selected for an oral presentation at 2019 AACR Annual Meetin
-
iOnctura selected for an oral presentation at 2019 AACR Annual Meeting
-
Artios Pharma Announces Appointment of Professor Rajesh Chopra as Non-Executive Director
-
M&A of the Year: Prexton Therapeutics
-
Asceneuron appoints Peter Van Vlasselaer as Chairman
-
ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors
-
Asceneuron appoints Dr. Thomas C. Wessel as Chief Medical Officer
-
Asceneuron initiates neuroimaging trial for tau modifier ASN120290
-
Ribometrix Announces $30 Million Series A Funding to Advance Pipeline of RNA-Targeting Small Molecule Therapies
-
Galecto Biotech Raises €79 Million in Series C Financing Co-Led by Ysios Capital and OrbiMed to Advance Galectin Inhibitor to Late-Stage Clinical Development
-
Rewind Therapeutics appoints leading neuroscience drug developer Ian J. Reynolds as Chief Executive Officer
-
VAXIMM Announces Regional Development and Commercialization Agreement with China Medical System Holdings
-
MACROPHAGE PHARMA ANNOUNCES APPOINTMENT OF LEADING INTERNATIONAL SCIENTIFIC ADVISORY BOARD
-
Vesalius Biocapital III Partners joins Forendo Pharma Investor Syndicate
-
ApoGen Biotechnologies Expands Series A Financing to $11 Million and Enhances Leadership Team
-
Artios Pharma Announces $84 million (£65 million) Series B Financing
-
Asceneuron’s tau modifier ASN120290 receives Orphan Drug Designation for progressive supranuclear palsy from the FDA
-
MOSA MEAT RAISES €7.5M TO COMMERCIALISE CULTURED MEAT
-
Forendo Pharma initiates phase I study for potential new, targeted treatment for endometriosis
-
Synaffix Further Strengthens Its Scientific Advisory Board with the Addition of John Lambert PhD, Former CSO of ImmunoGen
-
Akili Completes $55 Million Financing to Advance Company’s Digital Medicine Platform and Product Pipeline Aimed at Treating Cognitive Dysfunction
-
Medisafe Demonstrates Double-Digit Impact on Medication Adherence in Hypertension Patients
-
Macrophage Pharma Appoints Dr Michael Moore as Chairman
-
STORM Therapeutics wins Life Science Innovation Award
-
FORENDO PHARMA RECEIVES €3 MILLION LOAN FROM BUSINESS FINLAND TO DEVELOP NOVEL TREATMENTS FOR ENDOMETRIOSIS
-
Lundbeck to acquire Prexton Therapeutics adding foliglurax in clinical phase II to its pipeline of innovative treatments for patients suffering from Parkinson's disease
-
DAVID COLPMAN JOINS THE BOARD OF DIRECTORS OF FORENDO PHARMA
-
M Ventures Invests in CLEARink Displays
-
Artios exercises option to in-license potential first-in-class nuclease development programme
-
Artios Pharma Appoints Pierre Legault as Chairman of its Board of Directors
-
STORM Therapeutics Appoints Distinguished Professor and Nobel Prize Winner Professor Thomas Cech as Scientific Advisor
-
STORM Therapeutics Extends Series A Round to Include New Investor Taiho Ventures
-
Rewind Therapeutics secures 15.2 M EURO to develop novel remyelination therapies
-
aveni® S.A. Extends Copper Interconnects to 5nm and Below for BEOL Integration Using Innovative Electroplating Chemistry
-
STORM Therapeutics Announces Appointments to Scientific Advisory Board
-
Synaffix Launches toxSYN™, a New Platform of ADC Payloads
-
Akili Achieves Primary Efficacy Endpoint in Pediatric ADHD Pivotal Trial
-
Synaffix Commands IP Space of Glycan-Conjugated ADCs Through Major Expansion of Granted Patent Portfolio
-
iOnctura Announces Appointment of Leading International Scientific Advisory Board
-
Biolinq Completes $10M Series A Financing
-
STORM THERAPEUTICS ANNOUNCES PUBLICATION IN NATURE ON RNA EPIGENETICS BY FOUNDER PROFESSOR TONY KOUZARIDES
-
The IQVIA Institute for Human Data Science's Latest Report Names Medisafe as The Top Free & Publicly Available App for Medication Management
-
STORM Therapeutics Strengthens Board with Appointment of Professor Paul Workman, President and CEO of The Institute of Cancer Research
-
Two Global Leaders in Technology and Healthcare Join List of Venture Capitalists Investing in Wiliot to Scale IoT with Battery-Free Bluetooth
-
Padlock Therapeutics Appoints Adelene Perkins to Board of Directors
-
Taking RNA epigenetics by Storm
-
ADC Therapeutics Triggers Second Target-Specific License to Synaffix ADC Platform under Existing Agreement
-
FORENDO PHARMA NOMINATES WORLD CLASS SCIENTIFIC ADVISORY BOARD AND ELECTS PROFESSOR LINDA GIUDICE AS THE CHAIRPERSON
-
Synaffix Awarded "Runner Up" Postion for Best Platform ADc Technology
-
Artios Pharma wins Life Science Young Company of the Year and UK Private Finance Raise at the Biotech and Money Annual Awards 2017
-
VAXIMM Receives Orphan Designation for the European Union and the US for Oral T-cell Immunotherapy VXM01 to Treat Glioma
-
M Ventures participates in DNA Script' Successful Series A Fundraising of €11 M to Advance Development of its DNA Synthesis Technology
-
Artios Pharma appoints Dr Graeme Smith as Chief Scientific Officer
-
Macrophage Pharma Limited Extends Series A Round to Include New Investor M Ventures
-
ALCAN, a German Smart Antenna Start-up, Raises EUR 7.5 million to Manufacture Flat Panel Phased Array Antennas
-
Storm Therapeutics expands collaboration with Evotec on Storm's RNA Epigenetics Platform
-
Parkinson’s disease: Prexton announces initiation of phase II clinical testing
-
ObsEva Announces Presentations Related to its Assisted Reproductive Technology (ART) and Pre-term labor (PTL) Development Programs at ESHRE 2017 Annual Meeting
-
Artios announces formation of world-leading Scientific Advisory Board
-
ObsEva SA Announces the Completion of a Phase 1 PK/PD Clinical Trial Evaluating Different Doses of OBE2109 and Add-Back Therapy
-
VAXIMM Announces Data from Phase I Trial in Glioblastoma with Oral T-cell Immunotherapy VXM01 to be Presented at ASCO 2017 Annual Meeting
-
Synaffix Secures End-to-End Patent Protection of Its ADC Technology Platform as Its HydraSpace™ Patent Grants in the United States
-
ObsEva SA to Hold First Quarter 2017 Financial Results and Business Update Call on Thursday, May 18, 2017
-
VAXIMM Announces Collaboration with Merck KGaA, Darmstadt, Germany KGaA, Darmstadt, Germany, and Pfizer to Evaluate Combination of VXM01 with Avelumab in Glioblastoma and Colorectal Cancer in Phase I/II Clinical Studies
-
VAXIMM to present preclinical data on three novel oral T-cell immunotherapies at AACR Annual Meeting 2017
-
Calypso Biotech licenses CALY-001 best-in-class anti-MMP-9 antibody to EA Pharma
-
ObsEva SA to Attend Needham Annual Healthcare Conference in NYC
-
ObsEva Starts Phase 3 Clinical Program for Nolasiban in ART
-
Medisafe Raises $14.5M in Funding to Support Rapid Growth and Global Expansion
-
Storm Therapeutics appoints CEO and Chairman
-
New Data Demonstrate Significant Expansion of Therapeutic Index vs Cysteine-Engineered ADCs
-
Prexton Therapeutics Series B financing round raises €29 million ($31M) to advance its novel Parkinson’s therapeutic
-
ObsEva SA Announces Pricing of Initial Public Offering
-
ObsEva Expands Leadership Team and Board of Directors with Industry Veterans
-
ObsEva Announces Completion of Phase 1 First-in-Women Study of OBE022 for the Treatment of Preterm Labor
-
ARTSaVIT Ltd. Completes $6.3 Million Series A Financing
-
Key Synaffix Patent Covering Glycan-Conjugated ADC Process Granted in the United States
-
Asceneuron appoints J. Michael Ryan, M.D. as Chief Medical Officer
-
Artios Pharma Ltd: Strengthened Management Team with the Appointment of Dr Simon Boulton as Vice President Science Strategy
-
ObsEva Announces Results of the IMPLANT Phase 2 Trial of OBE001 (nolasiban) for the Improvement of Pregnancy and Live Birth Rates Following IVF/ICSI
-
Synaffix Enters into a Commercial License Agreement with ADC Therapeutics
-
ObsEva Announces Plans to Conduct Initial Public Offering in the United States
-
ObsEva Randomizes First Patient in Phase 2b EDELWEISS Study of OBE2109 for the Treatment of Endometriosis
-
iOmx Therapeutics raises EUR 40 million in Series A round
-
Artios Pharma Company Launch and Fundraising of $33.2 Million to Focus on Novel DNA Damage Response (DDR) Cancer Therapies
-
Parkinson’s disease: Prexton Therapeutics completes phase 1 clinical trial
-
Akili Adds Amgen Ventures and M Ventures* to Series B Financing, Increasing Round to $42.4 Million
-
Synaffix Achieves Significantly Improved Therapeutic Index Compared to Both FDA-Approved ADCs and Expands Its Scientific Advisory Board
-
Storm Therapeutics raises £12 million Series ‘A’ funding to target enzymes that modify RNA to generate novel cancer therapeutics
-
Cancer Metabolism Company Metabomed Completes $18 Million Series A Financing
-
Parkinson’s disease: Prexton Therapeutics starts phase 1 clinical trial
-
F-star Enters into Collaborative Discovery & Development Agreement with AbbVie for Bispecific Antibodies in Immuno-oncology
-
Padlock Therapeutics Creates West Coast Operations Appointing Scientific Co-founder Kerri Mowen, Ph.D., as Director of Biology Based in San Diego
-
Bird Rock Bio Announces Corporate Name Change from RuiYi, Inc.
-
ObsEva Closes CHF 60 (USD 60) Million in Series B Financing
-
Canbex Therapeutics announces start of Phase II trial of VSN16R for spasticity
-
Padlock Therapeutics - An unconventional approach to autoimmunity
-
F-star Appoints Dr Neil Brewis as Chief Scientific Officer
-
Padlock Therapeutics Named by FierceBiotech as a 2015 “Fierce15” Biotech Company
-
Asceneuron raises CHF 30 million in a Series A financing round led by Sofinnova Partners.
-
RaNA Therapeutics Secures $55 Million in Oversubscribed Series B Financing
-
Padlock Therapeutics Accelerates Pipeline Development Through Agreement with GSK
-
Raze Therapeutics Announces Addition of Robert Copeland, PhD, to Scientific Advisory Board
-
Chinese Consortium Enters into Agreement to Acquire Ambrx
-
Gilead Sciences Acquires EpiTherapeutics
-
Padlock Therapeutics Assembles Scientific Advisory Board with World Leaders in PAD Enzyme Biology and Autoimmune Disease
-
Announcing Progyny: Combining Best-in-Class Clinical Solutions with Consumer Expertise
-
Alzheimer's Drug Discovery Foundation awarded a USD 325,000 grant to support the development of Asceneuron's tau modulators
-
In new Nature paper, Raze Therapeutics co-founder David Sabatini discovers role for 1C metabolism in glioblastoma
-
Padlock Therapeutics Initiates Collaborations with Three Leading Research Partners on the Biology of PAD Enzymes
-
Raze Therapeutics Appoints Mark Manfredi as Chief Scientific Officer
-
The Eeva™ Test is Now Available to Help IVF Patients in the United States
-
Auxogyn and Fertility Authority to Merge
-
Asceneuron "The Road To Tau"
-
ObsEva Reports Positive Phase 1 Results for the First Orally Active Oxytocin Antagonist OBE001 to Treat Preterm Labour
-
Canbex Therapeutics enters into option agreement with Ipsen
-
Prexton Therapeutics raises 8.7 million euros (10 million dollars) in a Series A round
-
Asceneuron Appoints Leading Experts to Scientific Advisory Board
-
Evotec and Padlock Therapeutics announce initial success and extension of long-term collaboration
-
Raze Therapeutics Announces Addition of Julian Adams, PhD, George Q. Daley, MD, PhD, and Karen Vousden, PhD, to Scientific Advisory Board
